Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In breast tumors, PD-L1 expression levels are the highest in estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative (triple-negative) cancers.
|
31796994 |
2020 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
US specificity was lower in grade III (P < .001), estrogen receptor (ER)-negative (P < .001), progesterone receptor (PR)-negative (P = .004), HER2-positive (P = .015), triple-negative (P = .001), and larger breast tumors (P < .001).
|
31562691 |
2020 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Small molecule inhibitors (TKIs) of HER2 have demonstrated clinical benefit in HER2-positive breast tumors.
|
31765734 |
2020 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Women with HER2-positive breast tumors measuring ≥2 cm (median=5 cm) were randomized in a 1:2 ratio to 12 vs. 24 weeks of lapatinib and trastuzumab.
|
31662331 |
2020 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Acquired resistance to HER2-targeted therapies occurs frequently in HER2+ breast tumors and new strategies for overcoming resistance are needed.
|
31690671 |
2020 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Food and Drug Administration (FDA)-approved in February 2019, SQ trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2) protein in combination with hyaluronidase, offers an alternative dosage form for patients with breast tumors overexpressing HER2.
|
31595774 |
2020 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Compared with non-carriers, PALB2 pathogenic mutation carriers developed breast cancer at a younger age (47.52 years vs. 51.35 years, p = 0.016) and were more likely to have triple-negative (24.1% vs. 13.4%, p = 0.022) or HER2 negative (87.0% vs. 74.2%, p = 0.031) breast cancer and large breast tumors (> 2 cm) at diagnosis (72.2% vs. 57.0%, p = 0.024).
|
31768816 |
2020 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
IMPLICATIONS: This study demonstrates these functional fluorescent probes' ability to report metabolic adaptations during primary tumor growth, regression, residual disease, and regrowth in Her2 breast tumors.
|
30902832 |
2019 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We assessed antitumor effects of squalamine either alone or with trastuzumab in nude mice bearing breast tumor xenografts without (MCF-7) or with HER2-overexpression (MCF-7/HER-2).
|
30771431 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth receptor 2 (HER2) overexpressing breast tumors are known to be highly aggressive and metastatic.
|
30409762 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Since HER2 is associated with tumors of an epithelial region and most of the breast tumors originate in epithelial tissue, it is crucial to develop an approach to segment different tissue structures.
|
31163391 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Eleven (0.4%) cases of primary breast tumors with reported HER2 GH were identified over 76 months.
|
30892594 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Here we investigated the frequency of internodal HER2 heterogeneity in axillary lymph node macrometastases of BC patients and compared HER2 status between primary breast tumor and its metastases.
|
30957723 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> To evaluate the ability of texture analysis of breast dynamic contrast enhancement-magnetic resonance (DCE-MR) images in differentiating human epidermal growth factor receptor 2 (HER2) 2+ status of breast tumors.
|
31032222 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Trastuzumab-vcMMAE is an effective and selective agent for the treatment of HER2-positive breast tumors.
|
30246298 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We aimed to develop a long-acting delivery system for Herceptin, a HER2-targeting antibody, using injectable and thermosensitive hydrogels as the carrier to prevent the local relapse of HER2+ breast tumors while minimizing systemic side effects, especially cardiotoxicity.
|
31534538 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Immunohistochemical testing for estrogen receptor (ER), progesterone receptor (PR), human epidermal receptor factor-2 (HER-2), and Ki-67 proliferation index is performed daily to categorize breast tumors into different molecular subtypes.
|
30695671 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
|
31147552 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In summary, for the first time, we found that lncRNA ES3 was significantly upregulated in HER2-positive breast tumors and may contribute to breast cancer proliferation as a downstream target of HER2.
|
31211468 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Ninety five (52.5%) patients experienced axillary downstaging after PST, by molecular subtype 15% (3/20) in Luminal A, 46.4% (45/97) in Luminal B, 90.9% (20/22) in HER2+ and 70.3% (26/37) in triple negative breast tumours.
|
30744944 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We observed that triple-negative breast cancer (TNBC) and HER2+ non-luminal breast tumors were associated with more numerous CTLs and Tregs and a higher Treg/Th2 cell ratio as compared with luminal A subtype.
|
31016433 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The coexpression of WBP2 and HER2 in breast tumors was validated using IHC.
|
30593516 |
2019 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Utilizing an antibody against MZF1-pS27, we show that the phosphorylation of S27 correlates significantly (p < 0.0001) with high-level expression of ErbB2 in primary invasive breast tumors.
|
30622337 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Comprehensive biomarker analysis of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 labeling index was performed on each tissue block of 100 entirely submitted breast tumors in 99 patients.
|
30327501 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To assess for clonal replacement, we devise a summary statistic based on whole-exome sequencing of a pre-treatment biopsy and multi-region sampling of the post-treatment surgical specimen and apply this measure to five breast tumors treated with neoadjuvant HER2-targeted therapy.
|
30737380 |
2019 |